Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
Triple agonism based therapies for obesity (review
Two main types are commonly supplemented: L-carnitine tartrate, a common form found in sports nutrition supplements due to its rapid absorption rate, and acetyl L-carnitine (ALCAR), the most bioavailable form, which can cross the blood-brain barrier and is ideal for athletes and active people
Modern GLP-1 medications like semaglutide work by binding to GLP-1 receptors throughout the brain, gut, and pancreas
